Aberdeen Group plc Invests $2.53 Million in Lucid Diagnostics Inc. $LUCD

Aberdeen Group plc purchased a new stake in Lucid Diagnostics Inc. (NASDAQ:LUCD) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,500,000 shares of the company’s stock, valued at approximately $2,525,000. Aberdeen Group plc owned about 1.87% of Lucid Diagnostics at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. lifted its stake in shares of Lucid Diagnostics by 35.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock valued at $129,000 after purchasing an additional 22,727 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in Lucid Diagnostics during the 2nd quarter valued at $29,000. Cubist Systematic Strategies LLC bought a new stake in Lucid Diagnostics in the first quarter worth $39,000. SG Americas Securities LLC purchased a new position in Lucid Diagnostics during the third quarter worth $26,000. Finally, JPMorgan Chase & Co. boosted its stake in Lucid Diagnostics by 71,026.1% during the second quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock worth $38,000 after buying an additional 32,672 shares during the period. 74.01% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

LUCD has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Monday, December 29th. Wall Street Zen downgraded shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Needham & Company LLC restated a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a research report on Thursday, November 13th. Finally, Ascendiant Capital Markets increased their price target on Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $3.94.

Lucid Diagnostics Stock Performance

Lucid Diagnostics stock opened at $1.36 on Friday. The company has a market capitalization of $187.24 million, a PE ratio of -1.31 and a beta of 1.22. The company has a 50 day moving average price of $1.19 and a 200-day moving average price of $1.14. Lucid Diagnostics Inc. has a fifty-two week low of $0.95 and a fifty-two week high of $1.80.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.